ADPT 250516 7.50C(ADPT250516C7500) Stock Price Today

2.60
+1.90+271.43%

15min DelayClose May 2 15:59 ET

2.76High1.50Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Yesterday 04:45

Dig it! Hehehe

$Adaptive Biotechnologies (ADPT.US)$ Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025.

“We had a strong s...

105519319 MYname is

Apr 22 21:42

$Adaptive Biotechnologies (ADPT.US)$ OBLG guys!!!!

Teddy123

Apr 8 20:23

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

$Adaptive Biotechnologies (ADPT.US)$
Major Medicare Win: Adaptive's Cancer Test Gets 5-Year Coverage Extension

Trytosaveabit

Apr 8 20:03

Update

$Adaptive Biotechnologies (ADPT.US)$ Reuters
just
Adaptive Biotechnologies Receives Expanded Medicare Coverage of Clonoseq® for Surveillance in Mantle Cell Lymphoma

This_Guy

Dec 9, 2024 07:28

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

ADPT250516C7500

News

Comments